Peritoneal cancer is a highly complex and aggressive malignancy that develops in the peritoneum—the thin, silk-like membrane that lines the inner wall of the abdomen and covers most of the organs within it. Peritoneal cancer can be classified as Primary Peritoneal Cancer (PPC), which originates directly in the peritoneal cells (closely resembling epithelial ovarian cancer), or much more commonly, as Secondary Peritoneal Metastasis (Peritoneal Carcinomatosis). Secondary peritoneal cancer occurs when cancer cells shed or break away from primary gastrointestinal tumors (such as stomach, colorectal, appendix, or pancreatic cancers) and seed themselves across the extensive peritoneal surface.
Because the peritoneal cavity contains a small amount of lubricating fluid, cancer cells can spread easily across the abdominal space:
Peritoneal Seeding (Transcoelomic Spread): Tumor cells detach from a primary organ, travel through the peritoneal fluid, and attach to other areas on the peritoneal membrane, forming multiple small nodules (carcinomatosis).
Lymphatic Dissemination: Malignant cells enter the submesothelial lymphatic channels, spreading to retroperitoneal and mesenteric lymph nodes.
Direct Infiltration: Tumors grow directly into adjacent structures, such as the omentum (the protective fat layer in the abdomen), bowel loops, and diaphragmatic surfaces.
Primary Peritoneal Cancer shares many genetic risks with ovarian cancer, particularly mutations in the BRCA-1 and BRCA-2 genes. Secondary carcinomatosis is caused by advanced gastrointestinal or gynecological cancers. Other risk factors include advanced age, pelvic inflammatory conditions, and previous abdominal malignancies. Due to the protective peritoneal-blood barrier, traditional systemic chemotherapy often struggles to reach these surface tumors effectively. This makes specialized regional surgical interventions essential for successful treatment.
Accurately assessing Peritoneal Carcinomatosis is crucial for determining if cytoreductive surgery and HIPEC are suitable options:
Generates high-resolution, cross-sectional images of the chest, abdomen, and pelvis to detect ascites, peritoneal thickening, omental caking, and macroscopic tumor nodules across abdominal quadrants.
Combines anatomical imaging with metabolic tracking (using a glucose tracer) to identify hyperactive cancer nodes, check for extra-abdominal spread, and distinguish scar tissue from active peritoneal disease.
Offers excellent soft-tissue contrast to detect small bowel-surface implants and diaphragmatic nodules, which can sometimes be difficult to see on standard CT scans.
A clinical staging scoring system (ranging from 0 to 39) used to quantify the extent of cancer throughout 13 defined regions of the abdomen. Lower PCI scores generally indicate a higher likelihood of achieving complete surgical clearance.
Historically considered difficult to manage, peritoneal carcinomatosis is now actively treated using advanced combined-modality therapies. These specialized procedures offer patients a meaningful chance for long-term survival and cure.
CRS is a major surgical procedure aimed at removing all visible tumor nodules within the abdominal cavity. The surgeon carefully dissects affected tissue and may perform organ resections (such as removing the omentum, gallbladder, spleen, or segments of the bowel) to achieve **Complete Cytoreduction (CC-0)**, leaving no visible cancer behind.
Immediately following CRS, while the patient is still in the operating room, a heated chemotherapy solution (typically between **41°C and 43°C**) is circulated throughout the abdominal cavity for 60 to 90 minutes. This direct delivery bypasses the blood-peritoneum barrier, while the heat enhances the chemotherapy's ability to penetrate and destroy microscopic cancer cells.
An innovative, minimally invasive therapy designed for patients with advanced peritoneal cancer who may not be candidates for major open surgery. Chemotherapy is converted into a fine aerosol mist and administered under pressure directly into the abdomen during a laparoscopy, helping to stabilize disease and manage symptoms.
Depending on the primary source of the peritoneal spread, systemic chemotherapy is often combined with targeted therapies or immunotherapies. This treatment is administered either before surgery (neoadjuvant) to reduce the tumor load or after surgery (adjuvant) to maintain long-term disease control.
The success of advanced peritoneal treatments depends on several key parameters:
Completeness of Cytoreduction (CC Score):
The single most important prognostic factor. Achieving a CC-0 or CC-1 score (where no residual nodule larger than 2.5 mm remains) is critical for maximizing the survival benefits of HIPEC.
Primary Tumor Origin and Biology:
Peritoneal disease originating from appendiceal tumors (like pseudomyxoma peritonei) or colorectal cancer often responds more favorably to CRS and HIPEC compared to cancers of gastric or pancreatic origin.
Patient Selection and General Health:
Because CRS and HIPEC are intensive procedures, patients require good physical health, adequate heart and lung reserves, and optimal nutritional status to recover safely and avoid post-operative complications.
Specialized Surgical Expertise:
These procedures require a high level of technical skill. Dr. Prabhu Nesargikar and his dedicated multidisciplinary team utilize advanced surgical protocols to deliver safe, precise, and highly coordinated peritoneal care.